Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.51 |
| ▸ | LMNA | P02545 | 7/20 | 0.51 |
| ▸ | HPGD | P15428 | 7/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | MPO | P05164 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 4/20 | 0.46 |
| ▸ | HTT | P42858 | 4/20 | 0.46 |
| ▸ | NPC1 | O15118 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4882314 | 0.77 | CTRB1 (0.49) | LMNAHPGDHSD17B10ALDH1A1GAA | |
| SCHEMBL28983036 | 0.77 | KDM4E (0.56) | KDM4ELMNAHPGDHSD17B10ALDH1A1 | |
| SCHEMBL7315153 | 0.73 | KDM4E (0.59) | KDM4ELMNAHPGDHSD17B10ALDH1A1 | |
| SCHEMBL6105988 | 0.73 | LMNA (0.69) | KDM4ELMNAHPGDHSD17B10ALDH1A1 | |
| SCHEMBL6618728 | 0.72 | LMNA (0.67) | KDM4ELMNAHPGDHSD17B10ALDH1A1 | |
| SCHEMBL27822275 | 0.70 | KDM4E (0.56) | KDM4ELMNAHPGDHSD17B10ALDH1A1 | |
| SCHEMBL29052025 | 0.70 | KDM4E (0.60) | KDM4ELMNAHPGDHSD17B10ALDH1A1 | |
| SCHEMBL12083336 | 0.70 | KDM4E (0.70) | KDM4ELMNAHPGDHSD17B10ALDH1A1 | |
| SCHEMBL27379721 | 0.70 | KDM4E (0.65) | KDM4ELMNAHPGDHSD17B10ALDH1A1 | |
| SCHEMBL3225038 | 0.70 | KDM4E (0.65) | KDM4ELMNAHPGDHSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106977510-B | Process for preparing N-monofluoroalkyl tropanes | 通用电气健康护理有限公司 | 2021-06-08 | — | — | CN | disclosed |
| EP-2513099-B1 | PREPARATION OF N-MONOFLUOROALKYL TROPANES | GE HEALTHCARE LTD (GB) | 2019-11-20 | — | — | EP | disclosed |
| US-20160376265-A1 | PREPARATION OF N-MONOFLUOROALKYL COMPOUNDS | GE HEALTHCARE LIMITED (GB) | 2016-12-29 | — | — | US | disclosed |
| EP-2513099-A1 | PREPARATION OF N-MONOFLUOROALKYL TROPANES | GE Healthcare UK Limited (GB) | 2012-10-24 | — | — | EP | disclosed |
| US-20120244072-A1 | PREPARATION OF N-MONOFLUOROALKYL TROPANES | GE HEALTHCARE LIMITED (GB) | 2012-09-27 | — | — | US | disclosed |
| WO-2011073256-A1 | PREPARATION OF N-MONOFLUOROALKYL TROPANES | GE HEALTHCARE LIMITED (GB) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120244072-A1 | PREPARATION OF N-MONOFLUOROALKYL TROPANES | PFAS, CYP3A43, INMT | KDM4E 3667/4885LMNA 2578/4885HPGD 2850/4885 |
| US-20160376265-A1 | PREPARATION OF N-MONOFLUOROALKYL COMPOUNDS | PFAS, INMT, SLCO4C1 | KDM4E 3401/4885LMNA 2421/4885HPGD 2442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.